- Home
- BIOA vs RAPT Comparison
BIOA vs RAPT Comparison
Compare BIOA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- RAPT
- Stock Information
- Founded
- BIOA 2015
- RAPT 2015
- Country
- BIOA United States
- RAPT United States
- Employees
- BIOA N/A
- RAPT N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- BIOA Health Care
- RAPT Health Care
- Exchange
- BIOA Nasdaq
- RAPT Nasdaq
- Market Cap
- BIOA 175.7M
- RAPT 194.2M
- IPO Year
- BIOA 2024
- RAPT 2019
- Fundamental
- Price
- BIOA $5.45
- RAPT $26.62
- Analyst Decision
- BIOA Hold
- RAPT Buy
- Analyst Count
- BIOA 4
- RAPT 6
- Target Price
- BIOA $5.67
- RAPT $34.17
- AVG Volume (30 Days)
- BIOA 189.4K
- RAPT 180.1K
- Earning Date
- BIOA 11-06-2025
- RAPT 11-11-2025
- Dividend Yield
- BIOA N/A
- RAPT N/A
- EPS Growth
- BIOA N/A
- RAPT N/A
- EPS
- BIOA N/A
- RAPT N/A
- Revenue
- BIOA $3,863,000.00
- RAPT N/A
- Revenue This Year
- BIOA N/A
- RAPT N/A
- Revenue Next Year
- BIOA N/A
- RAPT N/A
- P/E Ratio
- BIOA N/A
- RAPT N/A
- Revenue Growth
- BIOA N/A
- RAPT N/A
- 52 Week Low
- BIOA $2.88
- RAPT $5.67
- 52 Week High
- BIOA $26.62
- RAPT $27.74
- Technical
- Relative Strength Index (RSI)
- BIOA 63.40
- RAPT 89.76
- Support Level
- BIOA $4.88
- RAPT $18.08
- Resistance Level
- BIOA $5.34
- RAPT $21.29
- Average True Range (ATR)
- BIOA 0.26
- RAPT 1.91
- MACD
- BIOA 0.04
- RAPT 0.91
- Stochastic Oscillator
- BIOA 95.06
- RAPT 92.12
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.